CARE Ratings upgrades SMS Pharmaceuticals’ short-term rating to CARE A1 and revises the long-term outlook to Positive, reaffirming the long-term rating at CARE A for ₹350.87 crore and upgrading short-term facilities to ₹52.83 crore.
AI Assistant
SMS Pharmaceuticals Ltd
2025
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.